Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benoit Beuselinck

Showing results (71-80 of 117) with videos related to

Pageof 12
Sort By:
Cancer|October 12, 2018
Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumSteven M Yip, Connor Wells, Raphael Moreira, et al.
Journal for Immunotherapy of Cancer|March 29, 2020
Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter studyNieves Martinez Chanza, Wanling Xie, Majd Issa, et al.
European Urology|August 26, 2019
First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database ConsortiumShaan Dudani, Jeffrey Graham, J Connor Wells, et al.
European Urology Oncology|December 2, 2019
Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint InhibitorsJeffrey Graham, Amishi Y Shah, J Connor Wells, et al.
Clinical Genitourinary Cancer|March 4, 2017
Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell CarcinomaGuillermo De Velasco, Wanling Xie, Frede Donskov, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 20, 2024
Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001Christopher Montemagno, Arnaud Jacquel, Charlotte Pandiani, et al.
European Urology Oncology|January 20, 2026
Outcomes of Patients with Metastatic Non-clear Cell Renal Cell Carcinoma Receiving Contemporary or Traditional First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Jeffrey Graham, David Maj, et al.
European Urology Oncology|November 1, 2023
Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Matthew S Ernst, Vishal Navani, et al.
Genome Medicine|August 13, 2010
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasetsCharles Swanton, James M Larkin, Marco Gerlinger, et al.
Journal of Clinical Medicine|February 25, 2022
Expanding the Role of Ultrasound for the Characterization of Renal MassesEduard Roussel, Riccardo Campi, Daniele Amparore, et al.
Pageof 12

Showing results (71-80 of 117) with videos related to

Sort By:
Pageof 12
Cancer|October 12, 2018
Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumSteven M Yip, Connor Wells, Raphael Moreira, et al.
Journal for Immunotherapy of Cancer|March 29, 2020
Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter studyNieves Martinez Chanza, Wanling Xie, Majd Issa, et al.
European Urology|August 26, 2019
First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database ConsortiumShaan Dudani, Jeffrey Graham, J Connor Wells, et al.
European Urology Oncology|December 2, 2019
Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint InhibitorsJeffrey Graham, Amishi Y Shah, J Connor Wells, et al.
Clinical Genitourinary Cancer|March 4, 2017
Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell CarcinomaGuillermo De Velasco, Wanling Xie, Frede Donskov, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 20, 2024
Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001Christopher Montemagno, Arnaud Jacquel, Charlotte Pandiani, et al.
European Urology Oncology|January 20, 2026
Outcomes of Patients with Metastatic Non-clear Cell Renal Cell Carcinoma Receiving Contemporary or Traditional First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Jeffrey Graham, David Maj, et al.
European Urology Oncology|November 1, 2023
Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Matthew S Ernst, Vishal Navani, et al.
Genome Medicine|August 13, 2010
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasetsCharles Swanton, James M Larkin, Marco Gerlinger, et al.
Journal of Clinical Medicine|February 25, 2022
Expanding the Role of Ultrasound for the Characterization of Renal MassesEduard Roussel, Riccardo Campi, Daniele Amparore, et al.
Pageof 12